Bioceramics and Biocomposites : (Record no. 9472)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 11071nam a22004693i 4500 |
| 001 - CONTROL NUMBER | |
| control field | EBC5741756 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | MiAaPQ |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240724113633.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d | |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr cnu|||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 240724s2019 xx o ||||0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781119372134 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9781119049340 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (MiAaPQ)EBC5741756 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (Au-PeEL)EBL5741756 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)1078955316 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | MiAaPQ |
| Language of cataloging | eng |
| Description conventions | rda |
| -- | pn |
| Transcribing agency | MiAaPQ |
| Modifying agency | MiAaPQ |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | R857.M3 .B563 2019 |
| 082 0# - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 610.28 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Antoniac, Iulian. |
| 245 10 - TITLE STATEMENT | |
| Title | Bioceramics and Biocomposites : |
| Remainder of title | From Research to Clinical Practice. |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 1st ed. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | Newark : |
| Name of producer, publisher, distributor, manufacturer | John Wiley & Sons, Incorporated, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2019. |
| 264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | ©2019. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (394 pages) |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Cover -- Title Page -- Copyright -- Contents -- List of Contributors -- Chapter 1 Multifunctionalized Ferri‐liposomes for Hyperthermia Induced Glioma Targeting and Brain Drug Delivery -- 1.1 Introduction -- 1.1.1 Blood-brain Barrier -- 1.1.1.1 What is the Blood-brain Barrier (BBB)? -- 1.1.1.2 The BBB Formation and Composition -- 1.1.1.3 Endothelial Cell and Tight Junctions -- 1.1.1.4 Astrocytes -- 1.1.1.5 Glioma -- 1.1.2 New Strategies for Measuring Drug Transport Across the BBB -- 1.2 Liposome -- 1.2.1 Introduction -- 1.2.2 Functionalization of Liposomes -- 1.2.2.1 PEGylation -- 1.2.2.2 Ligand‐mediated Liposome Targeting -- 1.2.2.3 Cell‐penetrating Peptide (CPP) Modification -- 1.2.3 Physiologically Modified Liposomes -- 1.2.3.1 PH‐sensitive Liposome -- 1.2.3.2 Thermosensitive Liposomes -- 1.2.4 Liposome in Combinational Therapies -- 1.2.4.1 CPP and Antibody Co‐delivery System -- 1.2.4.2 Superparamagnetic Iron Oxide Nanoparticles‐Induced Hyperthermia Treatment -- 1.3 Experimental -- 1.3.1 In Vitro BBB Model Set Up -- 1.3.2 Immunostaining and Confocal Imaging -- 1.4 Liposome Synthesis -- 1.4.1 Material Characterization -- 1.4.2 DOX Release and Loading Efficiency -- 1.4.3 Liposome Permeability Study -- References -- Chapter 2 Biofabrication Techniques for Ceramics and Composite Bone Scaffolds -- 2.1 Introduction -- 2.2 Scaffolds -- 2.2.1 Materials -- 2.3 Manufacturing Processes -- 2.3.1 Extrusion‐based Processes -- 2.3.2 Vat‐photopolymerization Processes -- 2.3.3 Powder Bed Fusion Processes -- 2.3.4 Inkjet Printing Processes -- 2.4 Conclusion -- References -- Chapter 3 Developments in Hydrogel‐based Scaffolds and Bioceramics for Bone Regeneration -- 3.1 Introduction -- 3.2 Directions in the Design of Hydrogels for Bone Regeneration -- 3.2.1 On the Preparation of Bioinspired and Biomimetic Hydrogels. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 3.2.2 Biofunctionalization of Non‐adhesive Macromolecules with Cell‐adhesive Peptides or Other Bioactive Molecules -- 3.2.3 Engineering of Synthetic Hydrogels with Bioactive or Biodegradable Sites -- 3.2.4 Nanoparticle‐loaded Fibrous Hydrogels for Bone Regeneration -- 3.2.5 Biomineralization and Hydrogels Bearing Negatively Charged Groups -- 3.2.5.1 Polymers Containing Acidic Functional Groups -- 3.2.5.2 Phosphorus‐containing Polymers Enhance Mineralization -- 3.3 Ca/P Biomaterials for Bone Regeneration -- 3.3.1 Introduction: Remaining Challenges -- 3.3.2 Micro‐ and Nanocomputed Tomography for the Study of Porous Ca/P Biomaterials -- 3.3.3 Preparation of 3D Porous Blocks and Granules of Ca/P Ceramics -- 3.3.3.1 Changing the Shape of Ca/P Granular Biomaterial Affects its Biomechanical Resistance -- 3.3.3.2 Changing the Shape of a Granular Biomaterial Affects its 3D Porosity -- 3.3.3.3 Changing the 3D Porosity of a Porous Biomaterial Modifies Liquid Diffusion -- 3.4 Perspectives -- Acknowledgments -- References -- Chapter 4 Zirconia‐Based Composites for Biomedical Applications -- 4.1 Introduction -- 4.2 Inert Ceramics for Biomedical Applications: Monolithic Al2O3 and ZrO2 -- 4.2.1 Alumina (a‐Al2O3) -- 4.2.2 Zirconia (ZrO2) -- 4.2.3 Inert Ceramics for Biomedical Applications: ZTA Composites -- 4.3 New Approach for Biomedical Grade Ceramics: Zirconia‐Based Composites -- 4.3.1 Y‐TZP/Al2O3 Composites -- 4.3.2 Ce‐TZP‐Based Composites -- 4.3.2.1 Ce‐TZP/Al2O3 Composites -- 4.3.2.2 Ce‐TZP/MgAl2O4 Composites -- 4.3.2.3 Ce‐TZP‐Based Composites Containing Elongated Grains -- 4.3.3 ZrO2/Hydroxyapatite Composites -- 4.4 Conclusion -- References -- Chapter 5 Bioceramics Derived from Marble and Sea Shells as Potential Bone Substitution Materials -- 5.1 Introduction -- 5.2 Biomimetic Approaches for Biomaterials Design -- 5.2.1 Apatites -- 5.2.2 Calcium Carbonates. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 5.3 Biogenic Precursors for Hydroxyapatite -- 5.3.1 Marble -- 5.3.2 Sea Shells -- 5.4 Synthesis Routes -- 5.4.1 Preparation of Precursors -- 5.4.2 Basic Techniques for Hydroxyapatite Synthesis -- 5.4.2.1 Wet Precipitation -- 5.4.2.2 Mechano‐Chemical Technique -- 5.4.2.3 Hydrothermal Technique -- 5.4.2.4 Sol-Gel Technique -- 5.4.2.5 Microemulsion by High‐Pressure Homogenization (HPH) -- 5.4.3 Synthesis of Hydroxyapatite by Thermal Treatment of Marble and Shells -- 5.4.3.1 Calcination of the Raw Material -- 5.4.3.2 Calcium Oxide Conversion into Hydroxyapatite -- 5.4.4 Synthesis of Hydroxyapatite by Chemical Treatment of Marble and Shells -- 5.4.4.1 Hydrothermal Methods -- 5.4.4.2 Sol-Gel Methods -- 5.4.4.3 Microemulsion by High‐Pressure Homogenization (HPH) -- 5.5 Processing of Marble and Shells‐Derived Hydroxyapatite -- 5.5.1 Thermal Processing of the Hydroxyapatite Powder -- 5.5.2 Dense Products (Pellets) -- 5.5.3 Porous Products (Scaffolds) -- 5.5.3.1 Conventional Processing Methods -- 5.5.3.2 Solid Free‐Form (SFF) Techniques -- 5.6 Material Characterization -- 5.6.1 Chemical Composition -- 5.6.2 Structure -- 5.6.2.1 X‐Ray Diffraction (XRD) Studies -- 5.6.2.2 Fourier Transformed Infrared (FT‐IR) Spectroscopy Analyses -- 5.6.3 Morphology -- 5.6.3.1 Morphology of Powders -- 5.6.3.2 Morphology of Dense Products (Pellets) -- 5.6.3.3 Morphology of Porous Products (Scaffolds) -- 5.6.4 Mechanical Properties -- 5.6.5 Thermal Stability -- 5.6.5.1 Dimensional Stability -- 5.6.5.2 Mass Stability -- 5.7 In vitro Behavior -- 5.7.1 Biocompatibility -- 5.8 Degradation in Biological Environment -- 5.9 In vivo Performance Evaluation -- 5.10 Conclusions -- Acknowledgment -- References -- Chapter 6 Bioglasses and Glass‐Ceramics in the Na2O-CaO-MgO-SiO2-P2O5-CaF2 System -- 6.1 Introduction -- 6.2 General Technical Aspects -- 6.3 Design of Compositions. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 6.3.1 CaO-MgO-SiO2 System -- 6.3.2 Na2O-CaO-SiO2 System -- 6.3.3 Modifications: Addition of B2O3, P2O5, CaF2, and Na2O to CaO-MgO-SiO2 System -- 6.4 Materials and Methods -- 6.4.1 Synthesis -- 6.4.2 Characterization Techniques -- 6.5 Structural Features of Glasses, Devitrification, and Materials' Properties -- 6.5.1 B‐ and Al‐Containing Glasses and Glass‐Ceramics -- 6.5.2 B‐Containing Glasses and Glass‐Ceramics (Al‐Free) -- 6.5.2.1 Glasses -- 6.5.2.2 Crystallization of Bulk Glasses -- 6.5.2.3 Glass‐Ceramics from Glass‐Powders Compacts -- 6.5.3 B‐Free (and Al‐Free) Glasses and Glass‐Ceramics -- 6.6 In vitro Biomineralization Ability (SBF Tests and HA Formation) -- 6.7 Cell Culture Testing and Tissue Response -- 6.8 Animal Testing and Clinical Tests -- 6.8.1 In vivo Animal Tests -- 6.8.2 Clinical Trials -- 6.9 Concluding Remarks -- Acknowledgments -- Bibliography -- Chapter 7 Electrical Functionalization and Fabrication of Nanostructured Hydroxyapatite Coatings -- 7.1 Introduction -- 7.2 Necessity and Prerequisites of Electrical Functionalization of Hydroxyapatite to Control Bone Cell Attachment -- 7.3 Computed Designing of Nanostructured Hydroxyapatite Electrical Potential (Structurally Depended Functionalization) -- 7.3.1 Introduction: Nanostructured HA as Assembled from Nanoclusters -- 7.4 HA Clusters and Nanoparticles (NPs) -- 7.4.1 Formation of HA Crystal from HA NPs in Various Conditions, Size, and Shape Effects -- 7.4.2 Main Features of Electrical Field, Charges, and Potential Inside and Outside of HA Surface -- 7.4.3 Bulk HA Crystal Structures Design (Infinite Periodical Lattice) and Electrical Potential -- 7.4.4 Imperfect Crystal with Defects -- 7.4.5 DOS for O, H, and OH Vacancies and H and OH Interstitials -- 7.4.6 Exploration of Influences of Various Atoms Substitutions in HA Structure and Properties. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 7.4.7 Studies of the Substitution Influences of Mg, Sr, and Si Atoms -- 7.4.8 Studies and Calculations of Mn and Se Substitutions -- 7.4.9 Combined DOS from Substituted Atoms and OH Vacancy -- 7.4.10 First Principle to Design HA Nanostructured Surface Properties -- 7.4.10.1 Super‐Cell and Slabs Approaches for HA "Surface‐Vacuum" Nanostructure Modeling - Various Versions of the Contemporary Developed Models and Calculations, Based on Different ab Initio/DFT Approaches -- 7.4.10.2 Surface Charges and Surface Energy for Different HA Surfaces with Different Stoichoimetry in Various Models -- 7.4.11 The Electron Work Function (from Data of the HA DFT Modeling) to Characterize HA Surface Electrical Charge -- 7.4.12 Characterization of Electrical Functionalization -- 7.4.13 Eguchi Originated Technique -- 7.4.14 Prethreshold Photoelectron Spectroscopy -- 7.5 Fabrication of Nanostructured Hydroxyapatite Coatings -- 7.5.1 rf‐Magnetron Technique -- 7.5.2 Engineering of CP Coatings Having Different Morphology and Structures -- 7.5.3 Doping of the CP Coating by Substitutions -- 7.5.4 Characterization of Coatings: Physical and Chemical Properties of rf‐Magnetron CP Coatings -- 7.5.5 The Biomedical Properties of rf‐Magnetron CP Coatings -- 7.6 Biological Properties of the Electrically Functionalized Hydroxyapatite Coatings -- 7.6.1 Introduction -- 7.7 Biocompatibility of Nanostructured and Electrically Functionalized Hydroxyapatite Coatings: Subcutaneous Model -- 7.7.1 Tissue and Bone in Vivo Growth on Electrically Functionalized Hydroxyapatite Coatings on the Titanium Substrate -- 7.8 General Conclusions -- References -- Chapter 8 Bioactive Micro‐arc Calcium Phosphate Coatings on Nanostructured and Ultrafine‐Grained Bioinert Metals and Alloys. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 8.1 Bioinert Alloys in Nanostructured and Ultrafine‐Grained States and Bioactive Calcium Phosphate Coatings for Medical Applications. |
| 588 ## - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Description based on publisher supplied metadata and other sources. |
| 590 ## - LOCAL NOTE (RLIN) | |
| Local note | Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Biomedical materials. |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Main entry heading | Antoniac, Iulian |
| Title | Bioceramics and Biocomposites |
| Place, publisher, and date of publication | Newark : John Wiley & Sons, Incorporated,c2019 |
| International Standard Book Number | 9781119049340 |
| 797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN) | |
| Corporate name or jurisdiction name as entry element | ProQuest (Firm) |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=5741756">https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=5741756</a> |
| Public note | Click to View |
No items available.